Dalcinonacog alfa LA is under clinical development by Gyre Therapeutics and currently in Phase II for Hemophilia B (Factor IX Deficiency). According to GlobalData, Phase II drugs for Hemophilia B (Factor IX Deficiency) have a 66% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Dalcinonacog alfa LA’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dalcinonacog alfa LA overview
CB-2679d (FIX-NG, recombinant factor IX) is under development for the treatment of hemophilia B. The drug candidate is a long acting next-generation coagulation Factor IX variant. It is administered through subcutaneous route and is based on the alterase technology.
Gyre Therapeutics overview
Gyre Therapeutics (Gyre), a subsidiary of GNI Group Ltd, is a biopharmaceutical company that develops and commercializes therapeutic drugs. The company’s pipeline products include hydronidone (F351) targets metabolic dysfunction associated steatohepatitis (MASH-associated liver fibrosis); pirfenidone for idiopathic pulmonary fibrosis; F573 treats acute-on-chronic liver failure; F528 and F230 and chronic obstructive pulmonary disease and pulmonary arterial hypertension, among others. It operates in the US and China. Gyre Therapeutics is headquartered in South San Francisco, California, the US.
For a complete picture of Dalcinonacog alfa LA’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
